Nasus Pharma Ltd. (NSRX)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20263 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Nasus Pharma Ltd.’s names, not what it holds today.
0 published
3 published
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Dec 19, 2023 | 11,844,859 | Dry powder compositions for intranasal delivery | Pharmaceuticals | Nasus Pharma Ltd. |
| Aug 2, 2022 | 11,400,045 | Treatment with powdered intranasal epinephrine | Pharmaceuticals | Nasus Pharma Ltd. |
| May 17, 2022 | 11,331,270 | Dry powder compositions for intranasal delivery | Pharmaceuticals | Nasus Pharma Ltd. |
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Apr 6, 2023 | 2023/0105615 | TREATMENT WITH POWDERED INTRANASAL EPINEPHRINE | Pharmaceuticals | Nasus Pharma Ltd. |
| Sep 16, 2021 | 2021/0283074 | Polymeric Compositions for Intranasal Administration | Pharmaceuticals | Nasus Pharma Ltd. |
| Sep 16, 2021 | 2021/0283050 | Treatment With Powdered Intranasal Epinephrine | Pharmaceuticals | Nasus Pharma Ltd. · patent 11,400,045 granted from it |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.